In the Media

May 21, 2018

BTV: InMed Pharmaceuticals Specializes in Developing Cannabinoid-based Therapeutics

InMed Pharmaceuticals specializes in developing cannabinoid-based therapeutics to treat serious diseases with high unmet medical needs.

Source: BTV

Share this post

Latest Articles

Epidermolysis Bullosa News: INM-755 Found Safe in 5 Adults With EB, Trial Opens to Adolescents

Epidermolysis Bullosa News writes about InMed’s Phase 2 clinical trial of INM-755 cannabinol cream, an investigational new treatment for epidermolysis bullosa. Excerpt: INM-755 was found to

July 29, 2022

The Dales Report – InMed Pharmaceuticals Unveils Industry Leading Portfolio

Jerry P. Griffin, VP of Sales and Marketing at BayMedica, InMed’s subsidiary, is interviewed by Shadd Dales of the The Dales Report to talk about

July 5, 2022

Pharma Tech Outlook: InMed Introduces THCV Into the Health and Wellness Industry

InMed’s THCV will bring ample opportunity to the health sector to scale up in the market. Read full story via Pharma Tech Outlook.

July 4, 2022